AI Insight
This study identifies ITPKB as a key molecular regulator that limits natural killer (NK) cell function during persistent stimulation, a state called desensitization that reduces their ability to fight tumors. Through comparative analysis of multiple mouse models, researchers found that blocking ITPKB genetically or with drugs restored NK cell activity by enhancing calcium signaling and improving their capacity to kill cancer cells. Both mouse and human NK cells showed improved antitumor responses when ITPKB was inhibited, including enhanced performance of CAR-NK cell therapies in animal models.
Why it matters
These findings could lead to new strategies for improving NK cell-based cancer immunotherapies by preventing the cells from becoming exhausted during treatment. Targeting ITPKB represents a potential approach to enhance both naturally occurring NK cells and engineered CAR-NK cell therapies, which are being developed as cancer treatments.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Natural Killer (NK) cell desensitization induced by persistent stimulation limits durable antitumor immunity, yet the molecular mechanisms governing this dysfunctional state remain poorly defined. To identify conserved regulators of NK cell desensitization, we performed comparative transcriptomic analyses across multiple murine models of persistent activation and dysfunction. This approach defined a shared transcriptional program of desensitization and identified Itpkb to be upregulated across multiple distinct contexts. Genetic and pharmacological inhibition of ITPKB enhanced degranulation, cytokine production, and cytotoxicity in both murine and human NK cells under multiple desensitization settings. Mechanistically, ITPKB regulated signaling downstream of persistent activation through the IP3/IP4 axis, limiting calcium mobilization and NFAT-dependent transcriptional responses in desensitized NK cells. Furthermore, inhibition or deletion of ITPKB enhanced NK-cell mediated tumor control in vivo and improved the efficacy of adoptively transferred CAR-NK cells, underscoring the translational potential of targeting this pathway. Together, these findings identify ITPKB as a cell-intrinsic regulator of NK cell desensitization and support targeting the IP3/IP4 signaling axis to enhance NK cell-mediated antitumor immunity.